Phase Ib/II study to assess efficacy, safety & immunological biomarker of anti PD-1 antibody with radiation therapy in patients with HER-2-negative metastatic breast cancer

Trial Profile

Phase Ib/II study to assess efficacy, safety & immunological biomarker of anti PD-1 antibody with radiation therapy in patients with HER-2-negative metastatic breast cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KBCRN-B-002
  • Most Recent Events

    • 09 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top